CCL14 exacerbates intraplaque vulnerability by promoting neovascularization in the human carotid plaque

Li, Zhuo; Qin, Z. H.; Kong, Xianwen; Chen, Baiqiang; Hu, Wenjie; Lin, Zhiqi; Feng, Yali; Li, Huanting; Wan, Qi; Li, Shifang

doi:10.1016/j.jstrokecerebrovasdis.2022.106670

Cited by 6 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found lower expression of CCL14 in DAHND lymphatic endothelial cells (Fig. 8E ), a chemokine previously associated with pathological neovascularization 70 . Taken together, these data suggest that angiogenic processes are likely not key to DAHND pathogenesis, despite the strongly pro-inflammatory microenvironment.…”

Section: Resultssupporting

confidence: 77%

Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells

Bangert,

Alkon,

Chennareddy

et al. 2024

Nat Commun

View full text Add to dashboard Cite

Dupilumab, an IL4R-blocking antibody, has shown clinical efficacy for atopic dermatitis (AD) treatment. In addition to conjunctivitis/blepharitis, the de novo appearance of head/neck dermatitis is now recognized as a distinct side effect, occurring in up to 10% of patients. Histopathological features distinct from AD suggest a drug effect, but exact underlying mechanisms remain unknown. We profiled punch biopsies from dupilumab-associated head and neck dermatitis (DAHND) by using single-cell RNA sequencing and compared data with untreated AD and healthy control skin. We show that dupilumab treatment was accompanied by normalization of IL-4/IL-13 downstream activity markers such as CCL13, CCL17, CCL18 and CCL26. By contrast, we found strong increases in type 22-associated markers (IL22, AHR) especially in oligoclonally expanded T cells, accompanied by enhanced keratinocyte activation and IL-22 receptor upregulation. Taken together, we demonstrate that dupilumab effectively dampens conventional type 2 inflammation in DAHND lesions, with concomitant hyperactivation of IL22-associated responses.

show abstract

Section: Resultssupporting

confidence: 77%

Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells

Bangert,

Alkon,

Chennareddy

et al. 2024

Nat Commun

View full text Add to dashboard Cite

show abstract

“…In previous studies, the production status of chemokines in the TME provided a predictive means for VEGF levels in cancer [11,30]. For example, CCL19 inhibits angiogenesis in colorectal cancer by inhibiting the Met/ERK/Elk-1/HIF-1α/VEGF-A pathway [14,31]. Our experimental results indicate that knocking down SCAF1 can promote the expression of CCL19, CCL14, and CCL11.…”

Section: Discussionmentioning

confidence: 51%

Identification of SCAF1 as a key factor affecting VEGF in LIHC and its potential target for therapy hypothesized based on network pharmacology and transcriptomics

Yu,

Zheng,

Tang

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: Liver hepatocellular carcinoma (LIHC) is a highly vascularized entity closely associated with immune functions, characterized by high incidence, elusive early detection, high malignancy, and poor prognosis. SCAF1 participates in the immune regulation mechanisms of various cancers (gliomas, breast cancer, etc.) and is involved in regulating the level of gene transcription. Nevertheless, there is currently no research focusing on the multiple mechanisms of SCAF1 in LIHC, including angiogenesis promotion and immunomodulation.Materials and Methods: In this study, we obtained TCGA data and utilized Weighted Gene Co-expression Network Analysis (WGCNA) to explore hub genes, followed by evaluating the prognostic and clinical significance of SCAF1. Functional identification of SCAF1 in LIHC was performed through enrichment analysis. Subsequently, the immune therapeutic effects of SCAF1 were explored using TIMER and TISIDB. Spatial transcriptomics and single-cell sequencing analysis based on GEO data were conducted to assess heterogeneity tissue within the tumor microenvironment. Finally, molecular docking predictions were performed using Perl to evaluate pharmacological effects.Results: We identified a significant upregulation of SCAF1 in LIHC, and its overexpression may lead to decreased patient survival rates, enhanced levels of angiogenesis, invasion, and migration capabilities in LIHC. Chemokine analysis results demonstrated that the up-regulation of SCAF1 expression could inhibit the expression of cell factors such as CCL19. Experimental results demonstrated that genistein could downregulate SCAF1 and VEGFA in LIHC and inhibit cell invasion and migration levels.Conclusion: SCAF1 can influence angiogenesis in LIHC and affect tumor progression and therapeutic outcomes in LIHC patients through angiogenesis regulation.

show abstract

Persistent acute kidney injury biomarkers: A systematic review and meta-analysis

Shi,

Jiang,

Song

et al. 2024

Clinica Chimica Acta

View full text Add to dashboard Cite

CCL14 exacerbates intraplaque vulnerability by promoting neovascularization in the human carotid plaque

Cited by 6 publications

References 33 publications

Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells

Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells

Identification of SCAF1 as a key factor affecting VEGF in LIHC and its potential target for therapy hypothesized based on network pharmacology and transcriptomics

Persistent acute kidney injury biomarkers: A systematic review and meta-analysis

Contact Info

Product

Resources

About